EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Novartis (Sweden)
Täby, SueciaPublicaciones en colaboración con investigadores/as de Novartis (Sweden) (12)
2022
-
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)
Breast Cancer Research and Treatment
2021
-
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Annals of Oncology, Vol. 32, Núm. 2, pp. 208-217
-
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
The Lancet Oncology, Vol. 22, Núm. 4, pp. 489-498
-
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Breast Cancer Research and Treatment, Vol. 189, Núm. 3, pp. 689-699
-
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 2005-2015
2020
-
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone receptor-positive HER2-negative breast cancer
Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6141-6148
-
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Annals of Oncology, Vol. 31, Núm. 8, pp. 1001-1010
2019
-
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
New England Journal of Medicine, Vol. 380, Núm. 20, pp. 1929-1940
-
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2
Oncologist, Vol. 24, Núm. 7, pp. 893-900
-
Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
European Journal of Cancer, Vol. 118, pp. 169-177
2018
2016
-
A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Annals of Oncology, Vol. 27, pp. vi98